Search
for
Sort by
Research 721–750 of 777
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- TNC+ fibroblasts involve in skin inflammation via neuro-immune and interacting with T cells
- Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: e-Posters
- An updated review of the sebaceous gland and its role in health and diseases Part 2: Pathophysiological clinical disorders of sebaceous glands
- Effects of mesenchymal stem cell therapy on alopecia areata in cellular and hair follicle organ culture models
- O PROCESSO DE ENFERMAGEM NO TRANSPLANTE CAPILAR: O IMPACTO DOS CUIDADOS PERIOPERATÓRIOS
- NUMERICAL DESCRIPTOR COMPUTATION OF ALOPECIA DRUGS USING COM – POLYNOMIAL
- Mendelian Randomization Identifies CD25+ CD4+ Tregs and Plasma Proteins in Androgenetic Alopecia Pathogenesis
- 013 IL-15/IL-15Rα signaling is a guardian of human hair follicle immune privilege and promotes hair growth
- Interleukin-15 is a hair follicle immune privilege guardian
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Alopecia areata – Current understanding and management
- Alopecia areata – Aktuelles Verständnis und Management
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
- Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
- 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- The Sebaceous Gland - Friend or Foe?
- Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report
- Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib